Contactin-1 IgG Cell Binding Assay, Serum
Use
The Contactin-1 IgG Cell Binding Assay is used primarily for evaluating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and related demyelinating peripheral neuropathies. It aids in determining contactin-1 IgG results as part of a profile. CIDP is an acquired, immune-mediated condition affecting peripheral nerves and nerve roots, leading to significant disability. Patients with antibodies targeting nodal-paranodal proteins, such as the neurofascin-155-contactin-1 complex, show common immunopathological mechanisms, distinct clinical features, and treatment responses.
Special Instructions
Not provided.
Limitations
A negative result does not rule out an immune-mediated demyelinating disease. The test should be used within the appropriate clinical context, and the administration of immunotherapy prior to sample collection may negatively impact the sensitivity of these assays. Interpretation of results should be made in consideration of the overall clinical presentation.
New York Approved
Methodology
Cell-based / Cytometry
Biomarkers
Contactin-1
Protein
LOINC Codes
- 101448-9 - CASPR1 IgG SerPl Ql CBA IFA
- 101448-9 - CASPR1 IgG SerPl Ql CBA IFA
Result Turnaround Time
5-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
3 mL
Minimum Volume
0.5 mL
Container
Red top or Serum gel
Collection Instructions
Centrifuge and aliquot serum into a plastic vial
Patient Preparation
For optimal antibody detection, specimen collection is recommended prior to starting immunosuppressant medication or intravenous immunoglobulin treatment (IVIg).
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |